1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.

TARO
Taro Pharmaceutical Industries Ltd.US flagNew York Stock Exchange
42.98
USD
+0.01
- -
1.62BMarket Cap

Total Valuation

Taro Pharmaceutical Industries Ltd. carries a market capitalization of 1.62B, placing it among publicly traded companies globally. Its enterprise value stands at 668.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.62B
Enterprise Value668.08M

Share Statistics

Taro Pharmaceutical Industries Ltd. currently has 37.58M shares outstanding.

Shares Outstanding37.58M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Taro Pharmaceutical Industries Ltd. trades at a trailing price-to-earnings ratio of 34.36.

PE Ratio34.36
PS Ratio2.57
PB RatioN/A
P/TBV Ratio0.89
P/FCF Ratio7.86
P/OCF Ratio10.99

Enterprise Valuation

On an enterprise value basis, Taro Pharmaceutical Industries Ltd. trades at an EV/EBITDA multiple of 12.00 and an EV/FCF ratio of 3.34. The EV/Sales ratio of 1.09 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.40 provides insight into valuation relative to core operating earnings.

EV / Sales1.09
EV / EBITDA12.00
EV / EBIT30.40
EV / FCF3.34

Financial Position

Taro Pharmaceutical Industries Ltd. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Current Ratio3.60
Quick Ratio3.03
Debt / EquityN/A
Debt / EBITDAN/A
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)4.23
Return on Invested Capital (ROIC)1.52
Return on Capital Employed (ROCE)1.06
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.96

Taxes

Over the trailing twelve months, Taro Pharmaceutical Industries Ltd. has paid 28.64M in income taxes, reflecting an effective tax rate of 38.52.

Income Tax28.64M
Effective Tax Rate38.52

Stock Price Statistics

Taro Pharmaceutical Industries Ltd.'s stock has gained approximately 13.09211% over the past 52 weeks. The 50-day moving average sits at 42.49, while the 200-day moving average is 40.19.

Beta (5Y)N/A
52-Week Price Change13.09211%
50-Day Moving Average42.49
200-Day Moving Average40.19
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Taro Pharmaceutical Industries Ltd. generated 610.83M in revenue and converted that into 45.70M in net income, yielding earnings per share of 1.22. EBITDA reached 55.65M, while operating income came in at 21.98M.

Revenue610.83M
Gross Profit293.28M
Operating Income21.98M
Pretax Income74.34M
Net Income45.70M
EBITDA55.65M
EBIT21.98M
Earnings Per Share (EPS)1.22

Balance Sheet

Cash & Cash Equivalents902.22M
Total DebtN/A
Net Debt-382.41M
Equity (Book Value)N/A
Book Value Per ShareN/A
Working Capital973.35M

Cash Flow

Taro Pharmaceutical Industries Ltd. produced 142.87M in operating cash flow over the past twelve months. After subtracting -56.87M in capital expenditures, free cash flow totaled 86.00M - equivalent to 2.29 per share.

Operating Cash Flow142.87M
Capital Expenditures-56.87M
Free Cash Flow86.00M
FCF Per Share2.29

Margins

Taro Pharmaceutical Industries Ltd. operates with a gross margin of 48.01, reflecting its pricing power and cost economics. The operating margin of 3.60 and net profit margin of 7.48 provide insight into operational efficiency.

Gross Margin48.01
Operating Margin3.60
Pretax Margin12.17
Profit Margin7.48
EBITDA Margin9.11

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder YieldN/A
FCF Yield12.72

Stock Splits

Taro Pharmaceutical Industries Ltd.'s most recent stock split took place on July 27, 2001 with a 1:2 split ratio.

Last Split Date7/27/2001
Split Ratio1:2

Scores

Taro Pharmaceutical Industries Ltd. posts an Altman Z-Score of 3.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.32